SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (844)4/25/2007 11:47:06 AM
From: tuck  Read Replies (1) of 897
 
I am actually still long ENCY (embarrassed <g> ). Ambrisentan approval is probably priced in (I'm still not sure it's a slam dunk, though). Now the other event . . . heh, heh . . . well, if you believe in trends, the FDA will say no again, go do another trial. Not sure what the odds of that really are; we're all just guessing as to the root problem with the NDA. What's the downside, you think, given approval in other countries? $2.50? Outright short, buy a bear spread . . . how to play?

And thanks for your AVNR summation.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News